4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …

Background In cardiovascular disease, prevention strategies targeting standard modifiable
cardiovascular risk factors (SMuRFs; hypertension, diabetes, hypercholesterolaemia, and …

Despite major advancements in cardiovascular medicine, sudden cardiac death (SCD)
continues to be an enormous medical and societal challenge, claiming millions of lives …

Ventricular arrhythmias are an important cause of morbidity and mortality and come in a
variety of forms, from single premature ventricular complexes to sustained ventricular …

Sudden cardiac death (SCD) from cardiac arrest is a major international public health
problem accounting for an estimated 15%–20% of all deaths. Although resuscitation rates …

Background Despite the high rate of sudden death after myocardial infarction among
patients with a low ejection fraction, implantable cardioverter–defibrillators are …

Material de distribuição exclusiva à classe médica. Os Arquivos Brasileiros de Cardiologia
não se responsabilizam pelo acesso indevido a seu conteúdo e que contrarie a …

Patients with chronic kidney disease (CKD) are predisposed to heart rhythm disorders,
including atrial fibrillation (AF)/atrial flutter, supraventricular tachycardias, ventricular …